Revolution Medicines, Inc. (RVMD) Misses Q4 EPS by 27c, provides guidance

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q4 EPS of ($1.14), $0.27 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $742 thousand versus the consensus estimate of $1.09 million.

GUIDANCE:

Revolution Medicines, Inc. sees FY2024 revenue of $(480)-(520) million, versus the consensus of $6.682 million.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• MP Materials seen largely insulated after China export-control move
• AeroVironment restates quarterly financials, citing $89M goodwill error